Edwards Lifesciences Corp (EW) : Picton Mahoney Asset Management scooped up 245,050 additional shares in Edwards Lifesciences Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 11, 2016. The investment management firm now holds a total of 434,950 shares of Edwards Lifesciences Corp which is valued at $44.8 Million.Edwards Lifesciences Corp makes up approximately 3.06% of Picton Mahoney Asset Management’s portfolio.
Other Hedge Funds, Including , Comerica Bank reduced its stake in EW by selling 11,131 shares or 9.41% in the most recent quarter. The Hedge Fund company now holds 107,172 shares of EW which is valued at $11 Million. Edwards Lifesciences Corp makes up approx 0.10% of Comerica Bank’s portfolio.Diversified Trust Co boosted its stake in EW in the latest quarter, The investment management firm added 71 additional shares and now holds a total of 21,929 shares of Edwards Lifesciences Corp which is valued at $2.3 Million. Edwards Lifesciences Corp makes up approx 0.33% of Diversified Trust Co’s portfolio.Aperio Group boosted its stake in EW in the latest quarter, The investment management firm added 14,332 additional shares and now holds a total of 58,208 shares of Edwards Lifesciences Corp which is valued at $6.2 Million. Edwards Lifesciences Corp makes up approx 0.05% of Aperio Group’s portfolio.Quantbot Technologies Lp reduced its stake in EW by selling 11,675 shares or 69.68% in the most recent quarter. The Hedge Fund company now holds 5,079 shares of EW which is valued at $539,441. Edwards Lifesciences Corp makes up approx 0.08% of Quantbot Technologies Lp’s portfolio.
Edwards Lifesciences Corp opened for trading at $103.34 and hit $104.92 on the upside on Monday, eventually ending the session at $104, with a gain of 0.98% or 1.01 points. The heightened volatility saw the trading volume jump to 26,45,661 shares. Company has a market cap of $22,023 M.
On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.
Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Outperform”, Firm has raised the Price Target to $ 125 from a previous price target of $110 .Company shares were Reiterated by Canaccord Genuity on Apr 27, 2016 to “Buy”, Firm has raised the Price Target to $ 123 from a previous price target of $113 .Company shares were Reiterated by Leerink Partners on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $93 .
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.